Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-04-03
2007-04-03
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S093100, C435S320100, C435S005000, C435S069500, C435S091200, C435S455000, C435S456000, C536S023720, C536S024100, C536S024200
Reexamination Certificate
active
11076190
ABSTRACT:
This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.
REFERENCES:
patent: 5112756 (1992-05-01), Bouillant et al.
patent: 5380830 (1995-01-01), Gonda
patent: 5817491 (1998-10-01), Yee et al.
patent: 6013516 (2000-01-01), Verma et al.
patent: WO 92/14829 (1992-09-01), None
patent: WO 99/15641 (1999-04-01), None
Thomson L. Human gene therapy: Harsh lessons, high hopes. FDA Comumer Magazine (2000) vol. 34, No. 5.
S. H. Orkin and A.G. Motulsky Report and recommendations of the panel to assess the NIH investment in research on gene therapy. Dec. 7, 1995, pp. 1-39.
Wall Transgenic Livestock: Progress and prospects for the future, Theriogenology, 1996, vol. 45, pp. 57-68.
Houdebine Production of pharmaceuticals proteins from transgenic animals, Journal of Biotechnology, 1994, vol. 34, pp. 269-287.
Hammer et al. Genetic engineering of mammalian embryos, Journal of Animal Science, 1986, vol. 63, 269-278.
Ebert et al. A Moloney MLV-Rat somatotropin fusion gene produces biologically active somatropin in a transgenic animal pig, Molecular Endocrinology, 1988, 277-282.
Mullins et al. Prospective series: Molecular Medicine in genetically engineered animasl, Journal of Clinical Investigations, 1996, vol. 97, No. 7, pp. 1557-1560.
Kappel et al. Regulating gene expression in transgenic animals, Current Opinion in Biotechnology, 1992, vol. 3, pp. 548-553.
Strojek et al. The use of transgenic animal techniques for livestock improvement, Genetic Engineering, 1988, vol. 10, pp. 221-245.
Berkowitz, et al., “Gene Transfer Systems Derived from Visna Virus: Analysis of Virus Production and Infectivity,”Virology, 279:116-129 (2001).
Buchschacher, et al., “Development of Lentiviral Vectors for Gene Therapy for Human Diseases,”Blood, 95(8):2499-2504 (Apr. 15, 2000).
Cullen, B.R., “Retroviruses as Model Systems for the Study of Nuclear RNA Export Pathways,”Virology, 249:203-210 (1998).
Gonda, et al., “Bovine Immunodeficiency Virus: Molecular Biology and Virus-Host Interactions,”Virus Res., 32:155-181 (1994).
International Search Report for PCT Application No. PCT/US00/33725, dated Aug. 21, 2001.
Kalvatchev, et al., “Acquired Immune Dysfunction in Rabbits Experimentally Infected with an Infectious Molecular Clone of the Bovine Immunodeficiency Virus (BIV127),”Viral Immunology, 8(3):159-164 (1995).
Kim, et al., “Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1,”Journal of Virology, 72(1):811-816 (Jan. 1998).
Mangeot, et al., “Development of Minimal Lentivirus Vectors Derived from Simian Immunodeficiency Virus (SIVmac251) and Their Use for Gene Transfer into Human Dendritic Cells,”Journal of Virology, 74(18):8307-8315 (Sep. 2000).
Sutton, et al., “Human Immunodeficiency Virus Type 1 Vectors Efficiently Transduce Human Hematopoietic Stem Cells,”Journal of Virology, 72(7):5781-5788 (Jul. 1998).
Trono, D., “Lentiviral Vectors: Turning a Deadly Foe into a Therapeutic Agent,”Gene Therapy, 7:20-23 (2000).
Walder, et al., “Bovine Immunodeficiency Virus in Experimentally Infected Rabbit: Tropism for Lymphoid and Nonlymphoid Tissues,”Comparative Immunology, Microbiology&Infectious Diseases, 24:1-20 (2001).
Wu, et al., “Development of a Novel Trans-Lentiviral Vector That Affords Predictable Safety,”Molecular Therapy, 2(1):47-55 (Jul. 2000).
Yu, et al., “Inducible Human Immunodeficiency Virus Type 1 Packaging Cell Lines,”Journal of Virology, 70(7):4530-4537 (Jul. 1996).
Soneoka, Y., et al., “A Transient Three-plasmid Expression System for the Production of High Titer Retroviral Vectors;” Nucleic Acids Research, 23(4):628-633 (1995).
Srinivasakumar, N., et al., “The Effect of Viral Regulatory Protein Expression on Gene Delivery by Human Immunodeficiency Virus Type 1 Vectors Produced in Stable Packaging Cell Lines;” Journal of Virology, 71(8):5841-5848 (Aug. 1997).
Bender, et al., “Evidence That the Packaging Signal of Moloney Murine Leukemia Virus Extends into thegagRegion,” J. Virol., 61(5):1639-1646 (May 1987).
Berkowitz, et al., “RNA Packaging,” Current Topics in Microbiology and Immunology, 214:177-218 (1996).
Buchschacher, et al., “Human Immunodeficiency Virus Vectors for Inducible Expression of Foreign Genes,” J. Virol., 66(5):2731-2739 (May 1992).
Burns, et al., “Vesicular Stomatitis Virus G Glycoprotein Pseudotyed Retroviral Vectors: Concentration to Very High Titer and Efficient Gene Transfer into Mammalian and NonmammalianCells,” Proc. Natl. Scad. Sci. USA, 90:8033-8037 (Sep. 1993).
Charneau, et al., “A Second Origin of DNA Plus-Strand Synthesis Is Required for Optimal Human Immunodeficiency Virus Replication,” J. Virol., 66(5) :2814-2820 (May 1992).
Gonda, et al., “Characterization and Molecular Cloning of a Bovine Lentivirus Related to Human Immunodeficiency Virus,” Nature, (1987): 330 (6146) : 388.
Kaye, et al., “cis-Acting Sequences Involved in Human Immunodeficiency Virus Type 1 RNA AD Packaging,” J. Virol. 69(10):6588-6592 (Oct. 1995).
Malim, et al., “The HIV-1rev trans-Activator Acts Through a Structured Target Sequence to Activate Nuclear Export of Unspliced Viral mRNA,” Nature, 338:254-257 (Mar. 16, 1989).
Markowitz, et al., “A Safe Packaging Line for Gene Transfer: Separating Viral Genes on Two Different Plasmids,” J. Virol., 62(4):1120-1124 (Apr. 1988).
Mitrophanous, et al., “Stable Gene Transfer to the Nervous System Using a Non-Primate Lentiviral Vector,” Gene Therapy, 6:1808-1818 (1999).
Miyoshi, et al., “Development of a Self-Inactivating Lentivirus Vector,” J. Virol. 72(10):8150-8157 (Oct. 1998).
Oberste, et al., “Characterization of Bovine Immunodeficiency VirusrevcDNAs and Identification and Subcellular Localization of the Rev Protein,” J. Virol., 67(11):6395-6405 (Nov. 1993).
Pear, et al., “Production of High-Titer Helper-Free Retroviruses by Transient Transfection,” Proc. Natl. Acad. Sci. USA, 90:8392-8396 (Sep. 1993).
Schwartz, et al., “Distinct RNA Sequences in thegagRegion of Human Immunodeficiency Virus Type 1 Decrease RNA Stability and Inhibit Expression in the Absence of Rev Protein,” J. Virol., 66(1):150-159 (Jan. 1992).
Yee, et al., “A General Method for the Generation of High-Titer, Pantropic Retroviral Vectors: Highly Efficient Infection of Primary Hepatocytes,” Proc. Natl. Acad. Sci. USA, 91:9564-9568 (Sep. 1994).
Zhu, et al., “Phenotypic Mixing Between Human Immunodeficiency Virus and Vesicular Stomatitis Virus or Herpes Simplex Virus,” J. Acq. Immune Deficiency Syndromes, 3:215-219 (1990).
Zufferey, et al., “Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery,” J. Virol., 72(12):9873-9880 (Dec. 1998).
Braun, et al., “Molecular Cloning of Biologically Active Proviruses of Bovine Immunodeficiency-like Virus,” Virology, 167:515-523 (1988).
Charneau, et al., “HIV-1 Reverse Transcription,” J. Mol. Biol., 241:651-662 (1994).
Garvey, et al., “Nucleotide Sequence and Genome Organ
Berkowitz Robert David
Kaleko Michael
Luo Tianci
Bell Boyd & Lloyd LLP
Campell Bruce R.
Novartis AG
Peng Bo
LandOfFree
Bovine immunodeficiency virus (BIV) based vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bovine immunodeficiency virus (BIV) based vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bovine immunodeficiency virus (BIV) based vectors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3746928